Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly and Company and Incyte Corporation have announced detailed data from the pivotal phase 3 RA-BEGIN study, which show…
Eli Lilly and Company has revealed plans to expand its global research and development (R&D) headquarters in Indianapolis, Indiana.
Eli Lilly and Company and Incyte Corporation announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.
Eli Lilly and Company and the ACCELERATE study’s academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of the investigational medicine evacetrapib, due to insufficient efficacy.
Eli Lilly and Company and Innovent Biologics, Inc. has announced an expansion of their drug development collaboration, already one of the largest in China between a multi-national and domestic biopharmaceutical company.
Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to…
Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, have announced financial commitment and continued scientific partnership to support the recently established Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) Study.
Eli Lilly and Company and Incyte Corporation have announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA).
Eli Lilly has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.